123207-57-8

Basic information

• Product Name: 4-(3-NITROBENZYL)MORPHOLINE
• Synonyms: 4-(3-NITROBENZYL)MORPHOLINE
• CAS NO: 123207-57-8
• Molecular Formula: C₁₁H₁₄N₂O₃
• Molecular Weight: 222.24
• Mol File: 123207-57-8.mol
• Article Data: 12

Chemical Properties

• Melting Point: 73 °C
• Boiling Point: 346.8°Cat760mmHg
• Flash Point: 163.5°C
• Appearance: /
• Density: 1.243g/cm³
• Vapor Pressure: 5.61E-05mmHg at 25°C
• Refractive Index: 1.578
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-(3-NITROBENZYL)MORPHOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3-NITROBENZYL)MORPHOLINE(123207-57-8)
• EPA Substance Registry System: 4-(3-NITROBENZYL)MORPHOLINE(123207-57-8)

Safety Data

• Hazardous Substances Data: 123207-57-8(Hazardous Substances Data)

Usage

General Description

4-(3-Nitrobenzyl)morpholine is a chemical compound with the molecular formula C11H13N2O3. It is a nitrobenzyl derivative of morpholine, and it is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. This chemical has the potential to be toxic if ingested, inhaled, or comes into contact with the skin or eyes, and proper safety precautions should be taken when handling and storing it. Its main applications include its use as a building block for the synthesis of various bioactive compounds and it can also be used as a reagent for organic synthesis. Additionally, it is important to note that 4-(3-Nitrobenzyl)morpholine is a flammable substance and should be stored and handled in accordance with safety regulations.

InChI:InChI=1/C11H14N2O3/c14-13(15)11-3-1-2-10(8-11)9-12-4-6-16-7-5-12/h1-3,8H,4-7,9H2

Upstream product

• 110-91-8 morpholine 
• 3958-57-4 1-bromomethyl-3-nitrobenzene 
• 99-61-6 3-nitro-benzaldehyde 

Downstream Products

• 206879-65-4 1-(4-(3-aminophenyl)piperazin-1-yl)ethanone 
• 123207-48-7 3-[(4-morpholinyl)methyl]aniline 

Relevant articles and documents

Activity of 2,6,9-trisubstituted purines as potent PDGFRα kinase inhibitors with antileukaemic activity

Receptor tyrosine kinase PDGFRα is often constitutively activated in various tumours and is regarded as a drug target. Here, we present a collection of 2,6,9-trisubstituted purines with nanomolar potency against PDGFRα and strong and selective cytotoxicity in the human eosinophilic leukaemia cell line EOL-1 that expresses the FIP1L1-PDGFRA oncogene. In treated EOL-1 cells, the example compound 14q inhibited the autophosphorylation of PDGFRα and the phosphorylation of STAT3 and ERK1/2. Interestingly, we observed pronounced and even increased effects of 14q on PDGFRα and some of its downstream signalling pathways after drug washout. In accordance with suppressed PDGFRα signalling, treated cells were arrested in the G1 phase of the cell cycle and eventually underwent apoptosis. Our results show that substituted purines can be used as specific modulators of eosinophilic leukaemia.

IMIDAZO-CONDENSED BICYCLES AS INHIBITORS OF DISCOIDIN DOMAIN RECEPTORS (DDRS)

The invention provides a compound of formula (I) (Formula (I)) or a tautomeric form, stereochemically isomeric form, N-oxide, pharmaceutically acceptable salt or solvate thereof, wherein R2, R3, R4, Ra, Rb

COMPOUNDS

A compound of formula (I): compositions and medicaments containing the same as well as processes for the preparation and use of such compounds, compositions and medicaments, particularly in diseases associated with inappropriate Aurora activity.